Loss of MED23 leads to poor prognosis in invasive breast cancer
Aliyeva, T.A.; Joseph, C.; Provenzano, E.; Russell, R.; Caldas, C.; Sonbul, S.; Nolan, C.; Green, A.R.; Rakha, E.A; Ellis, IO.; Mukherjee, A.
A. Mukherjee firstname.lastname@example.org
Purpose of the study: The molecular mechanism of lymphovascular invasion (LVI) which determines the early metastatic phenotype in breast cancer is still not fully understood. Lead from the METABRIC study revealed that MED23 correlated with negative LVI status (p=0.00005). Hence MED23 expression was studied at the protein level for correlations with LVI and other clinical-pathological parameters.
Methods: The METABRIC BC cohort (n=1980) was evaluated for MED23 mRNA expression and prognostic impact externally validated using the online bc-GenExminer 4.0. Correlation between MED23 protein expression with clinicopathological parameters, patient outcome and other biomarkers were explored (Nottingham Tenovus series; n=1255) using immunohistochemistry (IHC).
Results: High MED23 mRNA expression was negatively associated with tumour stage and was differentially expressed in good prognosis integrative clusters 7 and 8 (p
|Publication Date||Jun 20, 2017|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Aliyeva, T., Joseph, C., Provenzano, E., Russell, R., Caldas, C., Sonbul, S., …Mukherjee, A. (2017). Loss of MED23 leads to poor prognosis in invasive breast cancer|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf|
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf